Literature DB >> 8367454

Secretion of a single-gene-encoded immunoglobulin from myeloma cells.

L Shu1, C F Qi, J Schlom, S V Kashmiri.   

Abstract

We describe construction of a single gene encoding a single-chain immunoglobulin-like molecule. This single-gene approach circumvents inefficiencies inherent in delivering two genes into a mammalian cell and in the assembly of a functional immunoglobulin molecule. It would also facilitate ex vivo transfection of cells for gene-therapy protocols. SP2/0 murine myeloma cells transfected with the single gene SG delta CLCH1 expressed a single-chain protein, SC delta CLCH1, comprising approximately 60 kDa of the anti-carcinoma monoclonal antibody (mAb) CC49. The single-chain protein consisted of the heavy- and light-chain variable (VH and VL) domains of the mAb covalently joined through a short linker peptide, while the carboxyl end of the VL domain was linked to the amino terminus of the human gamma 1 Fc region through the hinge region. The single-chain protein assembled into a dimeric molecule, termed SCA delta CLCH1, of approximately 120 kDa and was secreted into the tissue culture fluid. SDS/PAGE analysis of the secreted immunoglobulin purified by protein G affinity chromatography confirmed the size of the molecule. The native mAb CC49 and SCA delta CLCH1 of CC49 showed similar binding to the tumor-associated glycoprotein TAG-72, and the chimeric mAb CC49 and SCA delta CLCH1 showed similar cytotoxic activity. This single-gene construct approach provides a way of generating an immunoglobulin-like molecule which retains the specificity, binding properties, and cytolytic activity of the chimeric mAb CC49. The immunoglobulin-like molecule SCA delta CLCH1 is potentially a therapeutic and diagnostic reagent against a range of human carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8367454      PMCID: PMC47274          DOI: 10.1073/pnas.90.17.7995

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.

Authors:  V G Johnson; J Schlom; A J Paterson; J Bennett; J L Magnani; D Colcher
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

2.  Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.

Authors:  A Kasid; S Morecki; P Aebersold; K Cornetta; K Culver; S Freeman; E Director; M T Lotze; R M Blaese; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.

Authors:  A Y Liu; R R Robinson; E D Murray; J A Ledbetter; I Hellström; K E Hellström
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

4.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Authors:  M H Tao; S L Morrison
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

6.  Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.

Authors:  A Molinolo; J F Simpson; A Thor; J Schlom
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

7.  Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen.

Authors:  N Hardman; L L Gill; R F De Winter; K Wagner; M Hollis; F Businger; D Ammaturo; F Buchegger; J P Mach; C Heusser
Journal:  Int J Cancer       Date:  1989-09-15       Impact factor: 7.396

8.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells.

Authors:  D Colcher; P H Hand; M Nuti; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

9.  Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.

Authors:  D Colcher; M F Minelli; M Roselli; R Muraro; D Simpson-Milenic; J Schlom
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

10.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.

Authors:  R Muraro; M Kuroki; D Wunderlich; D J Poole; D Colcher; A Thor; J W Greiner; J F Simpson; A Molinolo; P Noguchi
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

View more
  13 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.

Authors:  J Gan; K Kendra; M Ricci; J A Hank; S D Gillies; P M Sondel
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

3.  A switchable yeast display/secretion system.

Authors:  James A Van Deventer; Ryan L Kelly; Saravanan Rajan; K Dane Wittrup; Sachdev S Sidhu
Journal:  Protein Eng Des Sel       Date:  2015-09-01       Impact factor: 1.650

4.  Aberrant localization and underglycosylation of highly accumulating single-chain Fv-Fc antibodies in transgenic Arabidopsis seeds.

Authors:  Bart Van Droogenbroeck; Jingyuan Cao; Johannes Stadlmann; Friedrich Altmann; Sarah Colanesi; Stefan Hillmer; David G Robinson; Els Van Lerberge; Nancy Terryn; Marc Van Montagu; Mifang Liang; Ann Depicker; Geert De Jaeger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

5.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

Authors:  Scott M Knowles; Anna M Wu
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

6.  T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

Authors:  Claudia Geldres; Barbara Savoldo; Valentina Hoyos; Ignazio Caruana; Ming Zhang; Eric Yvon; Michele Del Vecchio; Chad J Creighton; Michael Ittmann; Soldano Ferrone; Gianpietro Dotti
Journal:  Clin Cancer Res       Date:  2013-12-13       Impact factor: 12.531

7.  Construction, characterization and crystal structure of a fluorescent single-chain Fv chimera.

Authors:  Nileena Velappan; Devin Close; Li-Wei Hung; Leslie Naranjo; Colin Hemez; Natasha DeVore; Donna K McCullough; Antonietta M Lillo; Geoffrey S Waldo; Andrew R M Bradbury
Journal:  Protein Eng Des Sel       Date:  2021-02-15       Impact factor: 1.650

8.  High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells.

Authors:  Volker Jäger; Konrad Büssow; Andreas Wagner; Susanne Weber; Michael Hust; André Frenzel; Thomas Schirrmann
Journal:  BMC Biotechnol       Date:  2013-06-26       Impact factor: 2.563

9.  Expression of antibody fragments with a controlled N-glycosylation pattern and induction of endoplasmic reticulum-derived vesicles in seeds of Arabidopsis.

Authors:  Andreas Loos; Bart Van Droogenbroeck; Stefan Hillmer; Josephine Grass; Martin Pabst; Alexandra Castilho; Renate Kunert; Mifang Liang; Elsa Arcalis; David G Robinson; Ann Depicker; Herta Steinkellner
Journal:  Plant Physiol       Date:  2011-02-16       Impact factor: 8.340

10.  A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.

Authors:  C De Lorenzo; A Tedesco; G Terrazzano; R Cozzolino; P Laccetti; R Piccoli; G D'Alessio
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.